FindTrial
Sign In

Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT05238311
Enrollment
Unknown
Registered
2022-02-14
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

refractory, relapsed

Brief summary

Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma

Detailed description

In Expanded Access, treating physicians are the Sponsors Expanded Access requests from treating physicians should be directed to www.pfizercares.com Availability will depend on location.

Interventions

DRUGElranatamab

Sponsors

Pfizer
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

Must have relapsed/refractory multiple myeloma (RRMM) and be refractory to at least one immunomodulatory drug, one proteasome inhibitor and one anti-CD38 antibody. Must have evidence of disease progression after last therapy. Must have exhausted all available treatment options accessible as local standard of care and not be eligible for participation in any ongoing clinical trial. Additional eligibility criteria may be required.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026